Memphis facility to make gene-editing treatment for sickle cell
In late 2022, Charles River completed an expansion project that increased clean room manufacturing capacity in Memphis by more than 50%. (Patrick Lantrip/The Daily Memphian file)
Boston-based Charles River Laboratories manufactures clinical and commercial cell and gene-modified cell therapies at its Shelby Drive facility.
Topics
Sickle Cell Disease Charles River Laboratories biotechAisling Mäki
Aisling Mäki has been writing about Memphis since she moved to the city more than 20 years ago. She’s worked for print, digital and broadcast news outlets, including Memphis Daily News and Action News 5 (WMC), as well as public relations agencies. Her work has earned awards from The Associated Press, Tennessee Press Association, Society of Professional Journalists and Public Relations Society of America.
Want to comment on our stories or respond to others? Join the conversation by subscribing now. Only paid subscribers can add their thoughts or upvote/downvote comments. Our commenting policy can be viewed here.